Diagnostic menu
Genetics & Pharmacogenetics
One DNA test. Lifelong genetic insight.
Saliva sample, collected at home or in clinic.
- SalivaNon-invasive collection
- 25 genesIn the pharmacogenetic panel
- 7 pathwaysPathway-focused gene groups
Clinical value
Clinical value for physicians
A saliva-based genetic test providing structured insight into genetic predispositions, biological pathways and medication response. It translates relevant genetic variation into structured, clinically contextualised insights.
Because inherited genetic information remains largely stable throughout life, it provides a long-term layer of information that clinicians can consider alongside medical history, phenotype, lifestyle and dynamic biomarkers.
- 01
Genetic predispositions
- Add inherited genetic context to the patient’s broader health profile
- 02
Medication response
- Review variants associated with drug metabolism alongside current medication and clinical factors
- 03
Pathway-level interpretation
- Explore biological pathways and genetic associations that add context
- 04
Personalised prevention
- Combine stable genetic information with phenotype, history, lifestyle and dynamic biomarkers
What is measured
What your patient sees
A lifelong genetic profile presented across practical health domains, designed to be understood in a clinical conversation. The physician remains central to interpretation, prescribing and treatment decisions.
Personal traits
Genetic traits relevant to individual health characteristics.Lifestyle insights
Genetic insights that can add context to lifestyle and preventive health discussions.Medication response
Genetic variants associated with potential differences in medication response.Genetic predispositions
Genetic variants associated with selected health conditions.Pharmacogenetic profile
Genetic information related to drug metabolism and selected pharmacogenetic pathways.Clinician dashboard
Consolidated findings, points of attention and pathway views for the clinician.
Inside the report
What the report shows
Clinician dashboard
- MTHFR
- MTR
- MTRR
- BHMT
- CBS
- COMT
- CYP1A2
- CYP2C19
- CYP2D6
- GSTM1
- NAT2
- UGT1A1
- SOD2
- CAT
- GPX1
- NQO1
- NOS3
- CYP1B1
- CYP19A1
- COMT
- SULT1A1
- GSTP1
Biochemical pathway view
Patient report
- CYP2C19Intermediate metaboliser
- CYP2D6Normal metaboliser
- SLCO1B1Decreased function
- VKORC1Typical sensitivity
- CardiovascularAverage
- Type 2 diabetesSlightly increased
- Alzheimer’s diseaseAverage
- Coeliac diseaseLow
- Caffeine metabolismFast
- Lactose toleranceLikely tolerant
- Muscle fibre typeMixed
- Alcohol flushUnlikely
Genes & markers included in the analysis
ABCG2, BCHE, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, F2, F5, HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, IFNL3, MTHFR, NUDT15, PROC, PROS1, SERPINC1, SLCO1B1, TPMT, UGT1A1, VKORC1
ACTN3, ADH1B, AHSG, ALDH2, ALDOB, AR, ATP7B, AUTS2, CCL2, CYP1A2, EBF1, EDA2R, F2, F5, FGF5, FUT2, HDAC9, HFE, HLA-DQA1, HLA-DQB1, IRF4, LCT, MAPT-AS1 (SPPL2C), MBL2, MX1, OAS1, PAX1/FOXA2, PROC, PROS1, SERPINA1, SERPINC1, SLC14A2, TAS2R38, WNT10A
ABCA1, ABCA4, ABCA7, ABO, ACE, APOB, APOC3, APOE, APC, BIN1, BRCA-pathway-related markers, CDKN2A/B, CLU, FTO, GBA, GCK, GCKR, HNF1B, IL6, IL6R, KCNJ11, KCNQ1, LPA, LRRK2, MAPT, MC4R, MTHFR, MUTYH, PCSK9, PNPLA3, PPARG, TCF7L2, TERT, TP53, TREM2 and more
MTHFR, MTR, MTHFD1, DHFR, MTRR, BHMT, MAT1A, AHCY, PEMT, GNMT, CBS, CTH, SUOX
SLCO1B1, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, NUDT15, BCHE, CYP1A1, CYP1B1, CYP2A6, CYP2C8, CYP2E1, CYP2F1, CYP4F2, ITPA, NQO1, PON1, ADH1B, ALDH2, GSTM1, GSTT1, GSTP1, GSTA1, UGT1A1, SULT1A1, SULT1E1, NAT1, NAT2, TPMT, COMT, BHMT, HNMT, PEMT, ABCB1, ABCG2, VKORC1
SOD2, CAT, GPX1, SOD3, GSTM1, GSTT1, GSTP1, GSTA1, G6PD, NOS3
CYP17A1, CYP19A1, SRD5A2, CYP1A1, CYP1A2, CYP1B1, CYP3A4, UGT1A1, COMT, GSTM1, GSTT1, GSTP1, GSTA1, SULT1A1, SULT1E1, NQO1, SOD2, SOD3, CAT, GPX1
TH, QDPR, DDC, COMT, MAOA, MAOB, DRD1, DRD2, DRD3, DRD4, DBH, ALDH2, ADRB2, HTR2A, HTR1A, HTR2B, DAO, HNMT, NAT2, OXTR, OPRM1, GABRA2, GRIK4, BDNF, VDR
BCO1, TTR, NBPF3, ALPL, MTHFR, FUT2, FUT6, TCN1, TCN2, CD320, MMUT, CLYBL, SLC23A1, SLC23A2, CYP2R1, GC, VDR, CYP27B1, DHCR7, SCARB1, CYP4F2, ZPR1, APOA5, APOB, VKORC1, TRPM6, TRPM7, CLDN16, CLDN19, SLC12A3
IL1A, IL1B, IL6, TNF / LTA, CRP, IL17A, IL10, IL1RN, IL6R, FKBP5, APOE, FADS1
What you get
Patient value
For the patient
- Understand predispositions: clear categories for inherited tendencies to discuss with a professional
- Medication guidance: where genetic variation may be associated with differences in medication response
- Lifelong relevance: inherited information is stable and stays relevant over time
For the clinician
- Selected pharmacogenetic genes: CYP2C19, CYP2C9, CYP2D6, CYP3A4/5, DPYD, SLCO1B1, TPMT, UGT1A1, VKORC1, NUDT15, BCHE, ABCG2
- Pathway views: methylation, drug metabolism, oxidative stress, estrogen metabolism, neurotransmitters, vitamins, inflammation
- Points of attention consolidated in one clinician dashboard
How it works
From saliva sample to clinical conversation
- 01
Collect
A saliva sample with a certified collection kit, at home or in clinic. - 02
Analyse
Genetic analysis in an ISO 15189-accredited laboratory. - 03
Review
The clinician reviews findings and pathway views in the dashboard. - 04
Discuss
Results are discussed with the patient in their clinical context.
Method and evidence
Secure. Accredited. Clinician-focused.
Information security
ISO 27001 certified.Laboratory
Genetic analyses are conducted in an ISO 15189-accredited laboratory.Sample collection
Saliva is collected with kits manufactured under an ISO 13485-certified quality management system.
Clinical value
How to use the results clinically
Genetic results should always be interpreted in clinical context.
- 01
Context first
Interpret inherited variants alongside medical history, phenotype, family history, current medication and relevant biomarkers. - 02
Communicate carefully
Genetic predisposition is not a diagnosis. Discuss associations and uncertainty within the patient’s broader clinical context. - 03
Prioritise
Focus the consultation on findings that may provide useful context for prevention, medication response or follow-up.
Measure → Intervene → Re-measure → Verify
White-label opportunity
Your programme. Your brand. Our infrastructure.
Genetics & Pharmacogenetics can be integrated into healthcare, longevity and preventive-health programmes as a branded or co-branded testing pathway, without building the laboratory infrastructure behind it.
- Branded test kits and packaging
- Integration into existing clinic or longevity programmes
- Remote sample collection
- Laboratory analysis
- A patient-facing experience in your name
- Results delivered into your preferred reporting environment
- Repeat testing and longitudinal programmes
Remote access
Sample collection at home, outside the clinic.A lifelong layer
Stable genetic context and medication-response insight from one saliva sample.Longitudinal use
Repeat testing to follow change over time.
Limitations
Clinical note
Pharmacogenetic information is intended to provide additional genetic context and should not replace professional judgement, current prescribing guidance or relevant patient-specific factors. Genetic predisposition is not a diagnosis.
Genetic associations should be considered alongside medical history, family history, phenotype, lifestyle and other relevant clinical information. The physician remains central to interpretation and all treatment-related decisions. Availability and regulatory status vary by market.
Contact
Thirty minutes, and you will know whether this fits your clinic.
Tell us how your clinic works today and which patients you see. We will go through the portfolio, what can be offered in your market, and what your team would need from us.